Home
Research
About
Services
Contact
Partners
Sign up
Blog
More
All Posts
Search
Andrew Keith
Mar 26
Diurnal Group - Efmody (Chronocort) recommended for approval in EU
Brian White
Mar 5
Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bn
Andrew Keith
Mar 3
Diurnal Group - A new dawn
Andrew Keith
Feb 22
Basilea's lisavanbulin
Brian White
Feb 12
Basilea reports further detail on derazantinib/checkpoint inhibitor combination
Brian White
Feb 10
Basilea reports positive results for derazantinib in biliary cancer
Brian White
Feb 9
Further good news from Basilea's Cresemba
Brian White
Feb 2
Diurnal Group JCEM publication
Andrew Keith
Jan 18
Diurnal Group and Chronocort
Brian White
Jan 14
Diurnal Business Update
Brian White
Jan 11
Basilea preliminary 2020 revenue and portfolio progress
Andrew Keith
Dec 21, 2020
Basilea's derazantinib - a differentiated FGFR inhibitor
Andrew Keith
Dec 7, 2020
Diurnal Group and Spruce Biosciences
Andrew Keith
Nov 13, 2020
Diurnal Group - Positive initial signs in the US for Alkindi
Andrew Keith
Nov 11, 2020
Diurnal Group - Unveiling DITEST
Andrew Keith
Oct 19, 2020
Introducing Basilea Pharmaceutica
Andrew Keith
Oct 9, 2020
Diurnal Group - Spruce Biosciences
